申请人:NIPPON SHINYAKU COMPANY, LIMITED
公开号:EP0655457A1
公开(公告)日:1995-05-31
A novel sialic acid derivative containing moranoline, represented by general formula (I), which has a cell fusion inhibitor activity and is useful as a medicine for preventing or treating inflammation and accompanying thrombosis, rheumatism, immuno-logical diseases, viral infections and cancer, wherein R¹ represents hydrogen or lower alkyl and R² represents hydroxy or lower alkoxy, or alternatively R¹ and R² may be combined together to represent a single bond; and R³s may be the same or different from one another and each represents hydrogen or acetyl.
一种新型的唾液酸衍生物,包含莫拉诺林,其通式表示为(I),具有细胞融合抑制剂活性,可用作预防或治疗炎症和伴随的血栓形成、风湿病、免疫疾病、病毒感染和癌症的药物。其中,R¹代表氢或低碳基,R²代表羟基或低烷氧基,或者R¹和R²可以结合在一起表示单键;R³可以相同或不同,每个代表氢或乙酰基。